Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2019 Jan 1;26(4):425–436. doi: 10.1530/ERC-19-0011

Figure 3. In vivo efficacy of palbociclib.

Figure 3.

A, NSG mice carrying THJ16T xenografts were treated with vehicle or 50mg/Kg/day palbociclib. B, Long term analysis of THJ16T proliferation treated continuously with 250nM (EC90) palbociclib. C, Western blot analysis of the expression of the indicated proteins in THJ16T and OCUT2 cells treated for 72 hours with 120nM (EC75) palbociclib.